Overall, our findings confirm that tumor biology—particularly proliferation index and hormone receptor status—was the main determinant of therapeutic decisions, underscoring the importance of reassessing biomarkers after surgery and reinforcing the paradigm of individualized, biology-driven treatment in breast cancer. Here, NR4A1 is linked to neoplasm.